Drugs / IFNα-Kinoid
IFNα-Kinoid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02665364 | Sep 2015 → Mar 2018 | systemic lupus erythematosus | Neovacs | Terminated | Mixed |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IFN-α kinoid | “IFN-α kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study.” PMID 31871140 ↗ Dec 2019 |
| Known as | IFN-K | “The safety and immunogenicity of the IFNα-Kinoid (IFN-K) have been evaluated in a phase I clinical study conducted in subjects with Systemic Lupus Erythematosus (SLE).” NCT02665364 ↗ |
| Known as | interferon-α kinoid | “To evaluate the efficacy and safety of the immunotherapeutic vaccine interferon-α kinoid (IFN-K) in a 36-week (W) phase IIb, randomised, double-blind, placebo (PBO)-controlled...” PMID 31871140 ↗ Dec 2019 |
| Modality | Vaccine | “immunotherapeutic vaccine interferon-α kinoid” PMID 31871140 ↗ Dec 2019 |
| Route | Intramuscular | “Patients with SLE (185) with moderate to severe disease activity and positive interferon (IFN) gene signature were randomised to receive IFN-K or PBO intramuscular injections” PMID 31871140 ↗ Dec 2019 |